Novel Fluorinated 8-Hydroxyquinoline Based Metal Ionophores for Exploring the Metal Hypothesis of Alzheimer's Disease

ACS Medicinal Chemistry Letters

Volumn 6, Issue 9, 2015, Pages 1025-1029

  Liang, Steven H ^a,b   Southon, Adam G ^c   Fraser, Benjamin H ^d   Krause Heuer, Anwen M ^d   Zhang, Bo ^d   Shoup, Timothy M ^a,b   Lewis, Rebecca ^a   Volitakis, Irene ^c   Han, Yifeng ^e   Greguric, Ivan ^d   Bush, Ashley I ^c   Vasdev, Neil ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

^e ZHEJIANG SCI TECH UNIVERSITY   (China)

Author keywords

8 Hydroxyquinoline; Alzheimer's disease; metal ionophore; positron emission tomography

Indexed keywords

4 DIMETHYLAMINOPYRIDINE; 5,7 DICHLORO 2 DIMETHYLAMINOMETHYL 8 QUINOLINOL; 8 QUINOLINOL DERIVATIVE; CLIOQUINOL; COPPER; IONOPHORE; N,N DIMETHYLFORMAMIDE; TETRAHYDROFURAN; THIOSEMICARBAZONE; TRIFLUOROACETIC ACID; ZINC ION;

ALZHEIMER DISEASE; ARTICLE; BRAIN TISSUE; DISEASE COURSE; FLUORINATION; HUMAN; MASS SPECTROMETRY; OLIGOMERIZATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 84941551634     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.5b00281     Document Type: Article

References (25)

1. Abbott, A. Dementia: A problem for our age Nature 2011, 475 (7355) S2-S4 10.1038/475S2a
2. Jakob-Roetne, R.; Jacobsen, H. Alzheimer's Disease: From Pathology to Therapeutic Approaches Angew. Chem., Int. Ed. 2009, 48 (17) 3030-59 10.1002/anie.200802808
3. Hamley, I. W. The Amyloid Beta Peptide: A Chemist's Perspective. Role in Alzheimer's and Fibrillization Chem. Rev. 2012, 112 (10) 5147-92 10.1021/cr3000994
4. Rodríguez-Rodríguez, C.; Telpoukhovskaia, M.; Orvig, C. The art of building multifunctional metal-binding agents from basic molecular scaffolds for the potential application in neurodegenerative diseases Coord. Chem. Rev. 2012, 256 (19-20) 2308-32 10.1016/j.ccr.2012.03.008
5. Bush, A. I. Drug Development Based on the Metals Hypothesis of Alzheimer's Disease J. Alzheimers Dis. 2008, 15 (2) 223-40
6. Crouch, P. J.; Barnham, K. J. Therapeutic Redistribution of Metal Ions To Treat Alzheimer's Disease Acc. Chem. Res. 2012, 45 (9) 1604-11 10.1021/ar300074t
7. Frederickson, C. J.; Koh, J.-Y.; Bush, A. I. The neurobiology of zinc in health and disease Nat. Rev. Neurosci. 2005, 6 (6) 449-62 10.1038/nrn1671
8. Watt, N. T.; Whitehouse, I. J.; Hooper, N. M. The Role of Zinc in Alzheimer's Disease Int. J. Alzheimer's Dis. 2011, 971021 10.4061/2011/971021
9. Bush, A. I.; Tanzi, R. E. Therapeutics for Alzheimer's Disease Based on the Metal Hypothesis Neurotherapeutics 2008, 5 (3) 421-32 10.1016/j.nurt.2008.05.001
10. Lee, J.-Y.; Mook-Jung, I.; Koh, J.-Y. Histochemically Reactive Zinc in Plaques of the Swedish Mutant β-Amyloid Precursor Protein Transgenic Mice J. Neurosci. 1999, 19 (11) RC10
11. Lovell, M. A.; Robertson, J. D.; Teesdale, W. J.; Campbell, J. L.; Markesbery, W. R. Copper, iron and zinc in Alzheimer's disease senile plaques J. Neurol. Sci. 1998, 158 (1) 47-52 10.1016/S0022-510X(98)00092-6
12. Suh, S. W.; Jensen, K. B.; Jensen, M. S.; Silva, D. S.; Kesslak, P. J.; Danscher, G.; Frederickson, C. J. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains Brain Res. 2000, 852 (2) 274-8 10.1016/S0006-8993(99)02096-X
13. Cherny, R. A.; Atwood, C. S.; Xilinas, M. E.; Gray, D. N.; Jones, W. D.; McLean, C. A.; Barnham, K. J.; Volitakis, I.; Fraser, F. W.; Kim, Y.-S.; Huang, X.; Goldstein, L. E.; Moir, R. D.; Lim, J. T.; Beyreuther, K.; Zheng, H.; Tanzi, R. E.; Masters, C. L.; Bush, A. I. Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits Aβ-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice Neuron 2001, 30 (3) 665-76 10.1016/S0896-6273(01)00317-8
14. Bareggi, S. R.; Cornelli, U. Clioquinol: Review of its Mechanisms of Action and Clinical Uses in Neurodegenerative Disorders CNS Neurosci. Ther. 2012, 18 (1) 41-6 10.1111/j.1755-5949.2010.00231.x
15. Clioquinol. http://www.alzforum.org/therapeutics/clioquinol.
16. Lannfelt, L.; Blennow, K.; Zetterberg, H.; Batsman, S.; Ames, D.; Harrison, J.; Masters, C. L.; Targum, S.; Bush, A. I.; Murdoch, R.; Wilson, J.; Ritchie, C. W. Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial Lancet Neurol. 2008, 7 (9) 779-86 10.1016/S1474-4422(08)70167-4
17. Huntington Study Group Reach2HD Investigators. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial Lancet Neurol. 2015, 14 (1) 39-47 10.1016/S1474-4422(14)70262-5
18. Papazian, V.; Jackson, T.; Pham, T.; Liu, X.; Greguric, I.; Loc'h, C.; Rowe, C.; Villemagne, V.; Masters, C. L.; Katsifis, A. The preparation of 123/125I-clioquinol for the study of Aβ protein in Alzheimer's disease J. Labelled Compd. Radiopharm. 2005, 48 (7) 473-84 10.1002/jlcr.942
19. Opazo, C.; Luza, S.; Villemagne, V. L.; Volitakis, I.; Rowe, C.; Barnham, K. J.; Strozyk, D.; Masters, C. L.; Cherny, R. A.; Bush, A. I. Radioiodinated clioquinol as a biomarker for β-amyloid: Zn2+ complexes in Alzheimer's disease Aging Cell 2006, 5 (1) 69-79 10.1111/j.1474-9726.2006.00196.x
20. Vasdev, N.; Cao, P.; van Oosten, E. M.; Wilson, A. A.; Houle, S.; Hao, G.; Sun, X.; Slavine, N.; Alhasan, M.; Antich, P. P.; Bonte, F. J.; Kulkarni, P. Synthesis and PET imaging studies of [18F]2-fluoroquinolin-8-ol ([18F]CABS13) in transgenic mouse models of Alzheimer's disease MedChemComm 2012, 3 (10) 1228-30 10.1039/c2md20075a
21. Liang, S. H.; Collier, T. L.; Rotstein, B. H.; Lewis, R.; Steck, M.; Vasdev, N. Rapid microfluidic flow hydrogenation for reduction or deprotection of 18F-labeled compounds Chem. Commun. 2013, 49 (78) 8755-7 10.1039/c3cc45166f
22. Liang, S. H.; Holland, J. P.; Stephenson, N. A.; Kassenbrock, A.; Rotstein, B. H.; Daignault, C. P.; Lewis, R.; Collier, L.; Hooker, J. M.; Vasdev, N. PET Neuroimaging Studies of [18F]CABS13 in a Double Transgenic Mouse Model of Alzheimer's Disease and Nonhuman Primates ACS Chem. Neurosci. 2015, 6 (4) 535-41 10.1021/acschemneuro.5b00055
23. Choi, J.-S.; Braymer, J. J.; Nanga, R. P. R.; Ramamoorthy, A.; Lim, M. H. Design of small molecules that target metal-Aβ species and regulate metal-induced Aβ aggregation and neurotoxicity Proc. Natl. Acad. Sci. U. S. A. 2010, 107 (51) 21990-5 10.1073/pnas.1006091107
24. Cary, B. P.; Brooks, A. F.; Fawaz, M. V.; Shao, X.; Desmond, T. J.; Carpenter, G. M.; Sherman, P.; Quesada, C. A.; Albin, R. L.; Scott, P. J. H. Targeting Metal-Aβ Aggregates with Bifunctional Radioligand [11C]L2-b and a Fluorine-18 Analogue [18F]FL2-b ACS Med. Chem. Lett. 2015, 6 (2) 112-6 10.1021/ml500413d
25. Hickey, J. L.; Lim, S.; Hayne, D. J.; Paterson, B. M.; White, J. M.; Villemagne, V. L.; Roselt, P.; Binns, D.; Cullinane, C.; Jeffery, C. M.; Price, R. I.; Barnham, K. J.; Donnelly, P. S. Diagnostic Imaging Agents for Alzheimer's Disease: Copper Radiopharmaceuticals that Target Aβ Plaques J. Am. Chem. Soc. 2013, 135 (43) 16120-32 10.1021/ja4057807